BRAF Mutations and Resistance of Non-Small Cell Lung Cancer to BRAF-Targeted Therapies Using Liquid Biopsy
Open Access
- 1 March 2021
- journal article
- editorial
- Published by Elsevier BV in Asia-Pacific Journal of Oncology Nursing
- Vol. 8 (2), 110-111
- https://doi.org/10.4103/2347-5625.308303
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancerAnnals of Oncology, 2018
- Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trialThe Lancet Oncology, 2017
- Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNAAnnals of Oncology, 2017
- Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trialThe Lancet Oncology, 2016
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)The Lancet, 2016
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsThe New England Journal of Medicine, 2015
- Molecular mechanisms of drug resistance and its reversal in cancerCritical Reviews in Biotechnology, 2015
- Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF MutationsJournal of Clinical Oncology, 2011
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008